Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.54 |
| ▸ | LPL | P06858 | 6/20 | 0.54 |
| ▸ | F11 | P03951 | 2/20 | 0.48 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | P4HB | P07237 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12989381 | 0.96 | LIPG (0.50) | LIPGLPLF11CYP4Z1F2 | |
| SCHEMBL1240002 | 0.89 | LIPG (0.55) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL1239924 | 0.86 | LIPG (0.56) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL67865 | 0.86 | LIPG (0.59) | LIPGLPLF11CYP4Z1F2 | |
| SCHEMBL19387552 | 0.85 | LMNA (0.41) | LIPGLPLF11CYP4Z1F2 | |
| SCHEMBL481948 | 0.85 | LIPG (0.53) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL1240538 | 0.85 | LIPG (0.47) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL1238076 | 0.85 | LIPG (0.47) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL23960089 | 0.83 | LIPG (0.59) | LIPGLPLF11CYP4Z1F2 | |
| SCHEMBL1239997 | 0.83 | ALDH1A1 (0.60) | LIPGLPLF11F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4719385-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | University of Vermont and State Agricultural College (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-3870287-B1 | BIARYL DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2024259007-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4476208-A1 | GLP-1R MODULATING COMPOUNDS | Ascletis Bioscience Co., Ltd. (CN) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024249380-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024206989-A2 | FLT3 INHIBITORS AND METHODS OF USING THE SAME | BIOVENTURES, LLC (US) | 2024-10-03 | — | — | WO | disclosed |
| CN-112912139-B | Biaryl derivatives | 第一三共株式会社 | 2024-07-09 | — | — | CN | disclosed |
| US-11932600-B2 | Biaryl derivative | DAIICHI SANKYO COMPANY LIMITED (JP) | 2024-03-19 | — | — | US | disclosed |
| WO-2011022508-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010101849-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010077882-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077882-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077883-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2196465-A1 | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
| WO-2006086609-A2 | INHIBITORS OF TRYPTASE | AXYS PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932600-B2 | Biaryl derivative | CA9, ACER2, CA2 | LIPG 621/4885LPL 490/4885F11 1529/4885 |
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | LIPG 91/4885LPL 88/4885F11 3242/4885 |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, CD2BP2 | LIPG 1065/4885LPL 1848/4885F11 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.